NurExone Biologic: The Preclinical Biotech Building Four Revenue Paths at Once (TSXV: NRX | OTCQB: NRXBF | FSE: J90)

Most preclinical biotech companies are single-indication, cash-burning bets. One drug, one indication, one binary FDA outcome years in the future, and steady dilution in the meantime. NurExone Biologic (NRX on the TSX Venture, NRXBF on the U.S. OTCQB, J90 on Frankfurt) is built differently.

The company is a preclinical Israeli biotech developing exosome-based nanodrugs. Exosomes are naturally occurring nanoparticles that the human body uses to move molecular cargo from one cell to another.NurExone scientists learned to load them with therapeutic payloads and use them as delivery vehicles. NurExone's platform, called ExoTherapy, has produced a lead candidate, ExoPTEN, which has earned Orphan Drug Designations from both the FDA and the EMA for acute spinal cord injury.

What is unusual about the setup is not the science alone. It is the structure of the company underneath.

Four potential revenue paths

The first is in-house development of ExoPTEN for acute spinal cord injury, targeting an IND submission in the first half of 2027.

The second is out-licensing of ExoPTEN for optic nerve regeneration, where a large preclinical study is expected at Sheba Medical Center. Preclinical animal work showed approximately 75 percent functional recovery in an optic nerve crush model.

The third is a U.S. subsidiary called ExoTop, positioned to generate near-term revenue from the production and distribution of naïve (unmodified) exosomes to the regenerative aesthetics, wellness, and longevity markets.. A distribution MOU with a partner in Mexico is already signed.

The fourth is licensing of the ExoTherapy platform itself for drug delivery applications in other indications.

Each path is at a different stage and carries its own risk. None is guaranteed. Together they add up to a structure that does not depend on any single clinical outcome to create value.

The structure underneath

The company was founded in 2020. It has raised over US$20 million since inception. There are approximately 90 million shares outstanding (as of December 2025). It was named to the TMX Venture 50 and closed a private placement in June 2026. Founder and Chairman Yoram Drucker previously co-founded Pluristem, BrainStorm Cell Therapeutics, and InnoCan Pharma. Past outcomes at other companies do not guarantee outcomes at NurExone.

The risks

NurExone is a preclinical biotech. The vast majority of preclinical drug candidates never reach regulatory approval. Animal data does not guarantee human outcomes. Orphan Drug Designation does not guarantee approval or commercial success. All four revenue paths depend on execution. Additional capital will be required and how it is structured will shape per-share outcomes.

What to watch

Near-term milestones include the IND submission for acute spinal cord injury (H1 2027), interim data from the Sheba optic nerve preclinical study, first ExoTop revenue, and further international patent grants.

The tickers are NRX on the TSX Venture Exchange, NRXBF on the U.S. OTCQB, and J90 on the Frankfurt Stock Exchange. For additional information, visit nurexone.com or public filings on SEDAR+.

Disclaimer: This content has been paid for by NurExone Biologic Inc. The author is not a registered investment advisor or medical professional. NurExone's products are in the preclinical stage and have not been tested in humans or approved by any regulatory authority. All scientific claims, pipeline details, and company data referenced come from NurExone Biologic Inc.'s public disclosures, corporate presentations, and press releases. Preclinical results referenced are from animal studies and do not guarantee similar outcomes in humans. Orphan Drug Designations referenced provide regulatory incentives including potential market exclusivity upon approval but do not guarantee clinical success, regulatory approval, or commercial viability. References to prior work by the Chairman, CEO, or other team members at other companies (including Pluristem, BrainStorm Cell Therapeutics, InnoCan Pharma, and Protalix Biotherapeutics) are historical and are not an indication of future performance at NurExone Biologic. Investing in preclinical biotech companies involves significant risk, including the possible loss of all capital invested. The majority of preclinical drug candidates never achieve regulatory approval. Readers should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.